Literature DB >> 10762692

Heregulin, but not ErbB2 or ErbB3, heterozygous mutant mice exhibit hyperactivity in multiple behavioral tasks.

R Gerlai1, P Pisacane, S Erickson.   

Abstract

Genetic redundancy is a problem in gene targeting studies because functionally relevant sister proteins can compensate for the lack of protein product of a targeted gene. A molecular system is chosen in which it is hoped to demonstrate both the lack and presence of compensation after disruption of particular single genes. Mammals may not be able to compensate for the lack of heregulin, a single ligand for multiple ErbB receptors, however, compensation is expected when a single ErbB receptor is knocked out. To investigate this the heregulin-1, ErbB2, or ErbB3 locus was disrupted in a targeted manner and mice heterozygous for the mutation were analyzed. Heregulin and its receptors were shown to be involved in embryonic brain development and, more recently, in plastic changes associated with adult brain function in rodents. Although they have never been shown to play roles in mammalian behavior, it was decided to characterize the mice behaviorally using a battery of simple tests. Heregulin mutant mice exhibited elevated activity levels in the open field, showed improved rotorod performance, and finished T-maze spontaneous alternation task faster compared to control wild type littermates, findings that suggest a consistent hyperactivity across tests. ErbB2 and ErbB3 mutant mice, whose strain origin was identical to that of heregulin mutants, showed no sign of the behavioral alterations. It is suggested that the abnormalities seen in heregulin mutant mice are due to mutation at that locus and the lack of alterations seen in ErbB2 and ErbB3 mutant mice is the result of compensation by unaltered sister receptors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10762692     DOI: 10.1016/s0166-4328(99)00175-8

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  55 in total

Review 1.  Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development.

Authors:  Christina Wilson; Alvin V Terry
Journal:  Clin Schizophr Relat Psychoses       Date:  2010-07

2.  Lack of the central nervous system- and neural crest-expressed forkhead gene Foxs1 affects motor function and body weight.

Authors:  Mikael Heglind; Anna Cederberg; Jorge Aquino; Guilherme Lucas; Patrik Ernfors; Sven Enerbäck
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

3.  Disruption of the neuregulin 1 gene in the rat alters HPA axis activity and behavioral responses to environmental stimuli.

Authors:  S B Taylor; A R Taylor; J A Markham; A M Geurts; B Z Kanaskie; J I Koenig
Journal:  Physiol Behav       Date:  2010-11-16

4.  Deficiency of Aph1B/C-gamma-secretase disturbs Nrg1 cleavage and sensorimotor gating that can be reversed with antipsychotic treatment.

Authors:  T Dejaegere; L Serneels; M K Schäfer; J Van Biervliet; K Horré; C Depboylu; D Alvarez-Fischer; A Herreman; M Willem; C Haass; G U Höglinger; R D'Hooge; B De Strooper
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-14       Impact factor: 11.205

5.  Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components.

Authors:  Ying-Jiun J Chen; Madeleine A Johnson; Michael D Lieberman; Rose E Goodchild; Scott Schobel; Nicole Lewandowski; Gorazd Rosoklija; Ruei-Che Liu; Jay A Gingrich; Scott Small; Holly Moore; Andrew J Dwork; David A Talmage; Lorna W Role
Journal:  J Neurosci       Date:  2008-07-02       Impact factor: 6.167

6.  Sex-specific neuroendocrine and behavioral phenotypes in hypomorphic Type II Neuregulin 1 rats.

Authors:  Sara B Taylor; Julie A Markham; Adam R Taylor; Brooke Z Kanaskie; James I Koenig
Journal:  Behav Brain Res       Date:  2011-05-19       Impact factor: 3.332

Review 7.  Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.

Authors:  Chao Deng; Bo Pan; Martin Engel; Xu-Feng Huang
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

Review 8.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

9.  Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons.

Authors:  Lei Wen; Yi-Sheng Lu; Xin-Hong Zhu; Xiao-Ming Li; Ran-Sook Woo; Yong-Jun Chen; Dong-Min Yin; Cary Lai; Alvin V Terry; Almira Vazdarjanova; Wen-Cheng Xiong; Lin Mei
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-29       Impact factor: 11.205

10.  Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice.

Authors:  A V Savonenko; T Melnikova; F M Laird; K-A Stewart; D L Price; P C Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.